Who Wins the U.S. Clinical AI Market? Abridge, Doximity, OpenEvidence, and Epic Go Head-to-Head
Four companies — Abridge, Doximity, OpenEvidence, and Epic — are competing to define the future of clinical AI in the United States.
At the center of this race is a documentation crisis that has pushed physicians to the edge of burnout and costs the healthcare system billions in administrative overhead. Each player is advancing with its own defensible moat, whether rooted in data, clinical expertise, or distribution. This is how the battle is unfolding.
The four companies in focus today all entered the market with a shared goal: transforming the point of care. Though each began with distinct strengths, they are evolving rapidly, absorbing even their competitors’ advantages in a bid to capture leadership in clinical AI.
So what strategies have they brought into this battle?
Let’s dive into this heated four-way race, examine the unique structure of the U.S. healthcare system, and identify the decisive formula that will determine the winners in AI healthcare.
Why U.S. Physicians Spend More Time Charting Than Caring
The issue that has pushed many U.S. clinicians into severe burnout is documentation. In the early 2010s, the Obama administration introduced the HITECH Act and used a mix of incentives and penalties to rapidly drive adoption of electronic health record, or EHR, systems. What began as a tool for efficiency and data sharing soon collided with the complexity of the U.S. insurance billing system and ended up placing an unexpected administrative burden on physicians.
The HITECH Act, enacted in 2009, pushed hospitals to adopt EHR systems through a combination of financial incentives and reimbursement penalties for non-adoption. The administrative load that followed was substantial. Clinicians were now required to log everything from patient registration data and insurance details to visit history, medications, procedure codes, and treatment consent forms — transforming the physician's role from caregiver to data entry operator.
Doctors now spend significant time outside of actual visits catching up on overdue charting, and documentation has become a symbol of the broader inefficiencies in the U.S. healthcare system.
AI scribe technology emerged as a way to relieve this burden. As doctors and patients talk naturally, a generative AI model listens in and produces a structured clinical note that fits medical context. Because it runs in the background without requiring extra clicks or manual input from the clinician, it is called an ambient scribe.
Ambient scribe technology has become one of the fastest-growing categories in clinical AI, attracting both venture capital and strategic investment from legacy EHR vendors. AI scribes began as simple documentation helpers but have steadily expanded their role as they combine with other types of medical AI. They now assist more directly with core clinical tasks such as diagnostic and prescribing suggestions and automated insurance coding.
The AI market that supports frontline clinical work is now reorganizing around the competition among four major players with very different backgrounds and business models: Abridge, Doximity, OpenEvidence, and Epic.
Four Players, Four Moats:
How Each Company Built Its Edge
Long before the term AI scribe became common, one dominant player had already built a stronghold with dictation technology. That company is Nuance, which has led the market with its medical dictation product Dragon Medical. To enter a market where such an incumbent is firmly established, AI startups have had to build distinctive moats of their own. Below, we look at what each player brings to the table.
Abridge: The Premium Enterprise Bet on Audit-Ready AI
Abridge has entered the race with a combination of technical depth and practical usefulness. Founded in 2018 by physicians at the University of Pittsburgh Medical Center, UPMC, the startup uses generative AI to convert doctor patient conversations into structured clinical notes in the SOAP format.
It goes well beyond simple transcription and delivers high quality notes that fully capture and organize medical context, which has helped Abridge win more than 150 large healthcare organizations as customers, including Kaiser Permanente and Mayo Clinic.
The company offers two capabilities that hospitals find especially valuable. Its patented Linked Evidence feature connects each sentence in the generated note back to the exact part of the original conversation, making it easier for clinicians and institutions to prepare for audits.
Its Contextual Reasoning Engine produces clinically useful summaries and billing codes that reflect both the patient’s history and the organization’s internal reimbursement rules, directly reducing administrative costs and helping maximize revenue. Because of this clear and measurable value, hospitals continue to pay for Abridge even as free services enter the market.
Doximity: Turning a Physician Network Into a Free AI Distribution Machine
Doximity competes on the strength of its vast physician network. When it was founded in 2010, the company attracted clinicians by offering a mobile, secure e fax service that let them comply with privacy regulations without relying on fax machines. As of 2025, more than 80 percent of U.S. physicians are members, making it the country’s largest professional network for doctors.
Doximity monetizes this traffic through advertising and job postings sold to pharmaceutical companies and hospitals. Its average revenue per physician user is very high at 228 dollars, and this scale has allowed it to build a business in which ads account for roughly 90 percent of total revenue.
Doximity entered the AI scribe market relatively late. To compensate, it chose a clear strategy: offer the service for free. Backed by advertising driven cash flow, the company launched Doximity Scribe at no cost in July 2025 and formally joined the AI race. That said, this heavy reliance on advertising also shapes how the market perceives the company, and many observers still see Doximity more as a media platform than a pure AI technology player.
OpenEvidence: From Medical Search Engine to AI Scribe — Funded by High-CPM Ads
OpenEvidence did not start out as an AI scribe. The company initially launched as a medical AI search engine built on a rigorously validated clinical knowledge base that helps physicians get accurate, diagnostic quality answers. By October 2025, it had grown into a service used by about 40 percent of U.S. physicians.
Like Doximity, it has found success with high margin advertising aimed at clinicians. Its ad inventory commands a CPM of 70 to 150 dollars, more than ten times the rates seen on general social networks, and this revenue has enabled OpenEvidence to offer its AI scribe features for free. With this approach, the company has reached an annualized revenue run rate of 50 million dollars in 2025.
However, concerns about ad driven models remain. There is a persistent risk that commercial interests could influence medical decision making. When advertising gets too close to clinical workflows, trust can erode, as shown by the case of EHR vendor Practice Fusion, which was punished after accepting illegal kickbacks and nudging physicians inside the system toward prescribing opioids. This history fuels ongoing unease about advertising that interacts directly with care delivery.
Epic: The $40B Incumbent That Every AI Startup Must Route Through
While startups compete with cutting edge AI, there is a major hurdle they must clear to gain a foothold in hospitals. Epic Systems, which holds roughly 40 percent of the U.S. hospital EHR market, stands directly in their path. Over its 46 year history, Epic has become deeply embedded in clinicians’ day to day workflows.
Epic deploys its software using a highly customized system integration model, tailoring implementations to each institution. As a result, hospitals face very high switching costs and find it difficult to move away from Epic to another vendor.
In effect, Epic has already built a robust legacy wall that rivals cannot easily breach. And as clinical AI expands from documentation into revenue cycle management — the billing and reimbursement workflows that determine hospital profitability — Epic's position at the center of hospital operations becomes even harder to dislodge.
The Convergence Play: Why Every Player Is Copying Every Other Player
The four companies have much more going on than the strengths already mentioned. As they study the market and refine their positions, they are also defending against and absorbing one another’s core features.
The boundaries between products are becoming blurred, and the market is moving toward integration and expansion. From the outside, the competition can feel like a relentless ping pong match, but underneath it is a careful calculation of survival and control.
Abridge: Partnering Into Epic's Backyard — and Beyond
Abridge works closely with Epic and became the first AI scribe company to be officially integrated into Epic’s EHR through a formal partnership program. In exchange for giving Epic equity and sharing part of its revenue, Abridge gained the ability to reach large hospital customers directly inside the EHR, without requiring clinicians to open a separate application, with integrated data flows as well.
In October 2025, Abridge also announced a partnership with Wolters Kluwer to embed UpToDate, one of the most trusted sources of clinical reference information, directly into its product. By offering reliable evidence alongside its scribing functions, Abridge is quickly expanding into territory traditionally associated with knowledge focused players such as OpenEvidence.
Doximity: Buying What It Couldn't Build
To shore up its relatively weaker AI capabilities, Doximity acquired Pathway Medical in August 2025. The goal is to move beyond basic transcription in Doximity Scribe and provide more accurate clinical knowledge summaries and question and answer support.
OpenEvidence: From Search Engine to Full Clinical Copilot
OpenEvidence’s technical evolution is also worth attention. In its early 2021 version, the company’s AI scribe was not tightly integrated with its knowledge database. Physicians had to manually key in patient information before they could receive diagnostic or prescribing suggestions.
Today, products such as DeepConsults and Visits are closing that gap. By leveraging exclusive content deals with major journals like NEJM and JAMA, OpenEvidence can now automatically analyze clinical conversations and suggest detailed diagnostic and treatment plans grounded in high quality source data.
Epic: Letting Partners In While Building Them Out
Epic is pursuing a dual strategy to maintain its dominance in the AI era while preserving its platform power. On one side, it runs the Pal program to bring leading AI solutions such as Abridge, Nuance DAX, and Ambience into its EHR environment. In January 2024, for example, Epic shipped an embedded version of Microsoft’s Nuance DAX Copilot, allowing external partners to operate smoothly within its system and increasing the value of the platform.
At the same time, Epic is investing heavily in building its own AI. Using data from 300 million patients, it is developing in house agents such as Art for AI scribing, Emmie for patient facing chat, and Penny for coding and reimbursement support. This approach lets Epic benefit from outside innovation in the short term while aiming in the long term to vertically integrate AI capabilities and tighten its grip on the AI scribe market.
Four Market Dynamics That Will Determine Who Actually Wins
Each player is expanding its presence with a powerful set of advantages, but in such a complex arena, AI performance alone is not enough to guarantee victory. Given the distinctive structure of the U.S. healthcare system and its business environment, the outcome is likely to be shaped by four core formulas
Dynamic 1: Free vs. Premium
— The Business Model Bifurcation
Doximity and OpenEvidence leverage unusually high CPMs for physician advertising, roughly ten times higher than general social platforms, to offer AI features for free and grow their user bases. Abridge, on the other hand, follows a premium strategy, demonstrating ROI for large hospitals in areas such as audit readiness and revenue uplift, then charging thousands of dollars per year in licensing fees. Companies are effectively forced to choose between free distribution powered by ads and high priced products that can clearly justify their cost.
Dynamic 2: EHR Integration Is the New Distribution
The critical question is whether an AI tool works inside the EHR workflow. OpenEvidence still operates mainly outside the EHR, usually in a browser context. Abridge, in contrast, is integrated directly into the Epic interface and can generate and send notes with a single click. This kind of workflow integration is becoming a non negotiable requirement for winning large hospital deals.
Dynamic 3: Market Segmentation, Not Monopoly
Even though consolidation among U.S. hospitals continues, independent practices still represent around 42 percent of the market. In an environment where large institutions and small clinics coexist, EHR ecosystems and risk tolerance differ widely, making a winner takes all outcome unlikely. The result is likely to be a landscape in which different companies secure leadership in different segments rather than a single universal winner.
Dynamic 4: The Real Endgame Is Revenue Cycle, Not Documentation
The endgame of AI competition is not simple documentation. Hospitals are businesses, and the major players are steadily expanding from note taking into revenue cycle management, the processes that govern reimbursement. AI scribe technology is evolving into an optimization engine that supports every step of the clinical workflow, from diagnosis and treatment to coding and claims, ultimately contributing to revenue performance.
The U.S. medical AI market is already fiercely contested. On one side, free models funded by advertising are becoming part of physicians' daily routines. On the other, high end paid offerings are pushing into major hospital systems. Epic, the dominant EHR platform, is reshaping the field through both external partnerships and internal innovation.
EHR vendors are especially important to watch. Beyond Epic, companies such as Oracle Cerner and athenahealth are also rolling out AI scribe products. These moves suggest that embedded, EHR native solutions may become a new standard.
What is clear is that this competition will not be settled by who transcribes conversations best. The real story is one of optimization rather than absolute dominance. Independent clinics focused on cost efficiency and large hospitals centered on risk management will gravitate toward different solutions that fit their needs, and the market is likely to become more segmented and more finely tuned.
Frequently Asked Questions
What is an AI scribe in healthcare?
An AI scribe is a tool that listens to physician-patient conversations and automatically generates structured clinical notes. Modern AI scribes use large language models to capture medical context, organize information into standard formats such as SOAP notes, and assist with diagnostic suggestions, billing codes, and treatment plans.
How does Abridge integrate with Epic?
Abridge is formally integrated into Epic's EHR through Epic's partnership program. Clinicians can generate and submit notes directly within the Epic interface without switching to a separate application.
Is Doximity Scribe free?
Yes. Doximity launched its AI scribe product at no cost to physicians in July 2025, funded by its advertising business.
What is OpenEvidence?
OpenEvidence started as a medical AI search engine built on a validated clinical knowledge base. By October 2025, it had grown into a service used by about 40 percent of U.S. physicians, and has since expanded into AI scribe functionality through products such as DeepConsults and Visits.
The U.S. clinical AI market is moving fast, and the competitive dynamics outlined here will continue to shift as new partnerships form and capital flows in.
If you are building or investing in this space, we would be glad to hear your perspective. For more analysis on healthcare AI and emerging technology sectors, explore the Kakao Ventures blog.